John Leonard, CFA
Special situations, micro-cap, contrarian, CFA

Oncology Diagnostics Company Biocept Is A Beaten Down IPO With Near Term Catalysts

Company overview

Biocept (NASDAQ:BIOC) is an oncology diagnostics company with one commercially available test (OncoCEE-BR for breast cancer).

Better detection for better treatment

There is an unmet need for an alternative to an invasive tissue biopsy given the inherent drawbacks. For example, as different parts of the same tumor can have different molecular features, this increases the potential for the pathologist to miss important biomarkers (used to determine the most appropriate treatment) as only a few thin slices of the tumor are analyzed. The mutation of tumors during treatment or disease progression may result in the initial tumor tissue being irrelevant. It may be impossible to even conduct a biopsy in certain cases such as when the cancer...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details